Long-Acting Octreotide for the Treatment and Symptomatic Relief of Bowel Obstruction in Advanced Ovarian Cancer
Authors:
- Michael V. SeidenMSMichael V. Seiden
- Maria RocheMRMaria Roche
- Carolyn KrasnerCKCarolyn Krasner
- Arlan F. FullerAFArlan F. Fuller
- Tina AtkinsonTATina Atkinson
- Alice KornblithAKAlice Kornblith
- Richard PensonRPRichard Penson
- 1 December 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 30 (6) , 563-569
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Aggressive pharmacological treatment for reversing malignant bowel obstructionJournal of Pain and Symptom Management, 2004
- The Role of Somatostatin and Octreotide in Bowel Obstruction: Pre-Clinic Al and Clinical ResultsTumori Journal, 2001
- Systematic Review of Surgery in Malignant Bowel Obstruction in Advanced Gynecological and Gastrointestinal CancerGynecologic Oncology, 1999
- Distribution of disease at autopsy in 100 women with ovarian cancerHuman Pathology, 1988
- MEDICAL MANAGEMENT OF INTESTINAL OBSTRUCTION IN PATIENTS WITH ADVANCED MALIGNANT DISEASEThe Lancet, 1985
- Survival after ovarian cancer induced intestinal obstructionGynecologic Oncology, 1982
- The management of ovarian-cancer-caused bowel obstructionGynecologic Oncology, 1981
- Intestinal operations in patients with ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1981
- Water absorption in experimental closed segment obstruction of the ileum in manThe American Journal of Surgery, 1971
- The absorption and secretion of fluid and electrolytes by the obstructed bowelBritish Journal of Surgery, 1965